T. N. Shuginova

T. N. Shuginova

Auto-generated profile, based on publicly available information

T. N. Shuginova

N. P. Napalkov Saint Petersburg Clinical Research and Practical Center for Specialized Healthcare (Oncology)

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 September 2021 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
EKE. A. Kushnareva
E. A. Kushnareva
TST. N. Shuginova
T. N. Shuginova
Aim. To analyze the spectrum of cancer types and baseline cardiovascular comorbidity in patients receiving checkpoint inhibitor therapy.Material and methods. We performed retrospective analysis of case records of 112 cancer patients (55 men and 57 women) who received checkpoint inhibitor therapy in St. Petersburg hospitals. We analyzed primary tumor localizations, received immunotherapy and the initial comorbid conditions in patients.Results. The mean age of patients at the time of anticancer therapy initiation was 59,7±12,1 years for men, 57,7±14,1 years for women (p=0,249). The most common indications for immunotherapy were the following localizations: melanoma (34,8%), lungs (21,4%) and urinary system (12,5%). Among women who received checkpoint inhibitors, the lung and gynecologic cancer had the same prevalence (17,5%). The vast majority of patients (85,7%) received antiPD-1 agents, while the anti-CTLA4+anti-PD-1 combination was received by only 8,6% of patients, anti-PD-L1 monotherapy — 5,7%. Before anticancer therapy initiation, 69,6% of patients had prior CVD and/or risk factors. There were following most common comorbid conditions: hypertension — 58,9%, coronary artery disease — 36,6%, heart failure — 24,1%. At the same time, men in comparison with women were more likely to have prior stroke (12,7% vs 1,75%, respectively, p=0,024). There were no other significant sex differences between the incidence of cardiovascular diseases.Conclusion. Based on current publications describing potential risk factors for cardiovascular complications of cancer immunotherapy with checkpoint inhibitors, among the patients included in this study, 87,5% of patients can be attributed to the high-risk group.

28 July 2023 in Kardiologiia
Verified
Journal Article
Closed access
PDF file
EKE. A. Kushnareva
E. A. Kushnareva
NGN. D. Gavriluk
N. D. Gavriluk
TST. N. Shuginova
T. N. Shuginova
EUE. L. Urumova
E. L. Urumova
EKE. V. Karelkina
E. V. Karelkina
OMOlga Moiseeva
Olga Moiseeva
Aim. To analyze the condition of the cardiovascular system in oncological patients receiving immune antitumor therapy with immune checkpoint inhibitors (CPIs) based on results of laboratory and instrumental examinations during a 3-month follow-up. Material and methods. This multicenter prospective observational study included 49 patients (25 men and 24 women aged 65.6±8.7 and 64.3±9.6 years, respectively). A laboratory screening (C-reactive proteins, troponin I, N-terminal pro-brain natriuretic peptide), EchoCG, and carotid ultrasound were performed for all patients. 27 patients were followed up at 3 months after the antitumor therapy initiation. Statistical analysis was performed with the StatPlus 8.0.3 software. Results. Incidence of cardiovascular complications was 16.3 %. The following significant changes in EchoCG parameters were observed: LV EF; (p=0.017), increased LV end-systolic volume (ESV) (р=0.023), and increased LV index of myocardial performance (LIMP; р=0.016). The degree of changes in ESV (ΔESV) depended on a history of chronic heart failure (р=0.03), whereas the degree of changes in EF (ΔEF) depended on the patient’s age at the initiation of antitumor therapy (р=0.006). Ultrasound showed an increase in maximum carotid stenosis (р=0.018). Conclusion. The study showed a high incidence of newly developed cardiovascular complications associated with the CPI treatment as well as the presence of changes in EchoCG parameters and data of carotid ultrasound.

1 November 2023 in Voprosy onkologii
Verified
Journal Article
Open access
ТШТатьяна Николаевна Шугинова
Татьяна Николаевна Шугинова
МСМария Александровна Симакова
Мария Александровна Симакова
FMFedor Moiseenko
Fedor Moiseenko
НШНаталия Леонидовна Шапорова
Наталия Леонидовна Шапорова
Lung cancer and chronic obstructive pulmonary disease (COPD) are the most common causes of death in patients worldwide. The etiology of these diseases is based on alterations in alveolocytes and other cells that form the lining of the surface of the respiratory tree. These alterations manifest in the context of persistent exposure to nicotine and tobacco combustion products. Persistent inflammation under conditions of impaired reparative processes, as well as changes at the level of epigenetic processes of regulation of the genome, take place in structural and functional changes in the lungs. Genomic-wide association studies among patients with COPD and lung cancer, aimed at identifying candidate genes for the development of these polygenic diseases, have revealed common loci of single nucleotide polymorphisms of cholinergic receptors of nicotinic alpha subunit CHRNA3 and CHRNA5, as well as regions in 4q31,4q24 and 5q, demonstrating the commonality of these pathologies. These data highlight the importance of expanding research on the interrelation and association between lung cancer and COPD. Рак легкого и хроническая обструктивная болезнь легких являются самыми распространенными причинами смерти пациентов во всем мире. В основе этиологии этих болезней лежат изменения альвеолоцитов и других клеток, выстилающих поверхность легочного дерева, возникающие на фоне хронического взаимодействия с никотином и продуктами горения табака. Персистирующее воспаление в условиях нарушенных репаративных процессов, а также изменения на уровне эпигенетических процессов регуляции работы генома реализуются в структурно-функциональных изменениях легких. Исследования общегеномных ассоциаций среди пациентов с хронической обструктивной болезнью легких и раком легкого, направленные на поиск генов-кандидатов развития этих полигенных заболеваний выявили общие локусы однонуклеотидных полиморфизмов холинергических рецепторов никотиновой альфа-субъединицы CHRNA3 и CHRNA5 и области в 4q31, 4q24 и 5q, что доказывает общность данных патологий. Эти данные подчеркивают важность расширения исследований, посвященных проблемам взаимосвязи и ассоциации рака легкого и хронической обструктивной болезни легких.

22 February 2026 in Cardiovascular Therapy and Prevention
Verified
Journal Article
Open access
PDF file
MSM. A. Simakova
M. A. Simakova
NGN. D. Gavriluk
N. D. Gavriluk
EKE. A. Kushnareva
E. A. Kushnareva
TST. N. Shuginova
T. N. Shuginova
FMFedor Moiseenko
Fedor Moiseenko
ESE. V. Shlyakhto
E. V. Shlyakhto
Поиск предикторов кардиотоксических эффектов ингибиторов контрольных точек иммунитета: результаты проспективного исследования